AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...

ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.

In Q3, the top 10 TV ad spenders poured a combined $544.8 million into airing their commercials, according to data shared ...

ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's ...

The insurer, which is the parent company for Harvard Pilgrim Health Care and Tufts Health Plan, said the reductions represent ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

The announced separation of the lower-growth orthopedics business will create an instant, stand-alone leader in this market ...

In March 2025, SFA Therapeutics announced that two head-to-head preclinical studies of its oral psoriasis therapy candidate, ...

This lens points to three standouts in retail, healthcare, and consumer goods. One pairs a modest yield with rapid hikes ...

For investors seeking passive income, probably the most important thing to know about Abbott is that it's a member of the ...

The cold and flu brand generated an impressions SOV of 4.71% and 2.9 billion impressions, primarily through CBS and its show GMA 3: What You Need to Know. The Proctor and Gamble brand invested $10.3 ...